Mathias J Rummel - JoVE Visualize

Showing results (11-20 of 21) with videos related to

Pageof 3

Sort By:

European Journal of Haematology|October 12, 2011

Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)Abderrahim Najaoui, Tamam Bakchoul, Johanna Stoy, et al.

Investigational New Drugs|December 21, 2007

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemiaMarkus Jensen, Andreas Engert, Florian Weissinger, et al.

Cancers|November 14, 2023

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384)Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, et al.

British Journal of Haematology|May 11, 2021

A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)Mathias J Rummel, Ann Janssens, David MacDonald, et al.

Leukemia & Lymphoma|May 10, 2002

Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cellsKai U Chow, Simone Boehrer, Joerg Bojunga, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2004

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancerSalah-Eddin Al-Batran, Akin Atmaca, Susanna Hegewisch-Becker, et al.

Haematologica|March 30, 2019

Glycoprotein V is a relevant immune target in patients with immune thrombocytopeniaRichard Vollenberg, Rabie Jouni, Peter A A Norris, et al.

Leukemia|August 16, 2022

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trialHeiner Zimmermann, Christian Koenecke, Martin H Dreyling, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphomaMathias J Rummel, Salah E Al-Batran, Soo-Z Kim, et al.

Blood|August 5, 2015

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.

Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:

Pageof 3

European Journal of Haematology|October 12, 2011

Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)Abderrahim Najaoui, Tamam Bakchoul, Johanna Stoy, et al.

Investigational New Drugs|December 21, 2007

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemiaMarkus Jensen, Andreas Engert, Florian Weissinger, et al.

Cancers|November 14, 2023

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384)Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, et al.

British Journal of Haematology|May 11, 2021

A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)Mathias J Rummel, Ann Janssens, David MacDonald, et al.

Leukemia & Lymphoma|May 10, 2002

Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cellsKai U Chow, Simone Boehrer, Joerg Bojunga, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2004

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancerSalah-Eddin Al-Batran, Akin Atmaca, Susanna Hegewisch-Becker, et al.

Haematologica|March 30, 2019

Glycoprotein V is a relevant immune target in patients with immune thrombocytopeniaRichard Vollenberg, Rabie Jouni, Peter A A Norris, et al.

Leukemia|August 16, 2022

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trialHeiner Zimmermann, Christian Koenecke, Martin H Dreyling, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphomaMathias J Rummel, Salah E Al-Batran, Soo-Z Kim, et al.

Blood|August 5, 2015

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.

Pageof 3